Unlocking the predictive potential of long non-coding RNAs: a machine learning approach for precise cancer patient prognosis

References

• Nurk S, Koren S, Rhie A, et al. The complete sequence of a human genome. Science. 2022;376(6588):1–16. doi:10.1126/science.abj6987.
   Web of Science ®Google Scholar
• Chan JJ, Tay Y. Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):1310. doi:10.3390/ijms19051310.
   Web of Science ®Google Scholar
• Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. GPB. 2016;14(1):42–54. doi:10.1016/j.gpb.2015.09.006.
   Google Scholar
• Loewer S, Cabili MN, Guttman M, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113–1117. doi:10.1038/ng.710.
   PubMed Web of Science ®Google Scholar
• Fernandes JCR, Acuña SM, Aoki JI, et al. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Noncoding RNA. 2019;5(1):17. doi:10.3390/ncrna5010017.
   PubMed Web of Science ®Google Scholar
• Yang Z, Jiang S, Shang J, et al. LncRNA: shedding light on mechanisms and opportunities in fibrosis and aging. Ageing Res Rev. 2019;52:17–31. doi:10.1016/j.arr.2019.04.001.
   PubMed Web of Science ®Google Scholar
• Wu H, Li A, Zheng Q, et al. LncRNA LZTS1-AS1 induces proliferation, metastasis and inhibits autophagy of pancreatic cancer cells through the miR-532/TWIST1 signaling pathway. Cancer Cell Int. 2023;23(1):130. doi:10.1186/s12935-023-02979-7.
   PubMed Web of Science ®Google Scholar
• Xu J, Wu KJ, Jia QJ, et al. Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B. 2020;21(9):673–689. doi:10.1631/jzus.B1900709.
   PubMed Web of Science ®Google Scholar
• Liang J, Ye C, Chen K, et al. Non-coding RNAs in breast cancer: with a focus on glucose metabolism reprogramming. Discov Oncol. 2023;14(1):72. doi:10.1007/s12672-023-00687-2.
   PubMedGoogle Scholar
• Misawa A, Takayama KI, Inoue S. Long non-coding RNAs and prostate cancer. Cancer Sci. 2017;108(11):2107–2114. doi:10.1111/cas.13352.
   PubMed Web of Science ®Google Scholar
• Cheng X, Zeng Z, Yang H, et al. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma. BMC Cancer. 2023;23(1):105. doi:10.1186/s12885-023-10584-0.
   PubMed Web of Science ®Google Scholar
• Poulet C, Njock MS, Moermans C, et al. Exosomal long non-coding RNAs in lung diseases. Int J Mol Sci. 2020;21(10):3580. doi:10.3390/ijms21103580.
   PubMed Web of Science ®Google Scholar
• Entezari M, Ghanbarirad M, Taheriazam A, et al. Long non-coding RNAs and exosomal lncRNAs: potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomed Pharmacother. 2022;150:112963. doi:10.1016/j.biopha.2022.112963.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li T, Wang Z, et al. lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway. J Cell Mol Med. 2020;24(14):8236–8247. doi:10.1111/jcmm.15499.
   PubMed Web of Science ®Google Scholar
• Wu W, Zhao Y, Gao E, et al. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p. J Cell Mol Med. 2020;24(1):441–450. doi:10.1111/jcmm.14749.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Sun W, Qin Z, et al. LncRNA regulation: new frontiers in epigenetic solutions to drug chemoresistance. Biochem Pharmacol. 2021;189:114228. doi:10.1016/j.bcp.2020.114228.
   PubMed Web of Science ®Google Scholar
• Gao P, Wei GH. Genomic insight into the role of lncRNA in cancer susceptibility. Int J Mol Sci. 2017;18(6):1239. doi:10.3390/ijms18061239.
   Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584.
   PubMed Web of Science ®Google Scholar
• O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010–2020. doi:10.1093/eurheartj/eht439.
   PubMed Web of Science ®Google Scholar
• Paixião GMM, Santos BC, Araujo RM, Ribeior MH, Moraes JL, Ribeiro: Machine Learning in Medicine: Review and Applicability. Arg Bras Cardiol. 2022;118(1):95–102.
   Google Scholar
• Moshawrab M, Adda M, Bouzouane A, et al. Reviewing federated machine learning and its use in diseases prediction. Sensors. 2023;23(4):2112. doi:10.3390/s23042112.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093.
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi:10.1073/pnas.191367098.
   PubMed Web of Science ®Google Scholar
• Meng J, Li P, Zhang Q, et al. A four-long non-coding RNA signature in predicting breast cancer survival. J Exp Clin Cancer Res. 2014;33(1):84. doi:10.1186/s13046-014-0084-7.
   PubMedGoogle Scholar
• Sun M, Wu D, Zhou K, et al. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network. Breast Cancer Res Treat. 2019;175(1):59–75. doi:10.1007/s10549-019-05147-6.
   PubMed Web of Science ®Google Scholar
• Liu Z, Mi M, Li X, et al. A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer. J Cell Mol Med. 2020;24(21):12444–12456. doi:10.1111/jcmm.15762.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. doi:10.1038/nrclinonc.2016.66.
   PubMed Web of Science ®Google Scholar
• Li X, Li Y, Yu X, et al. Identification and validation of stemness-related lncRNA prognostic signature for breast cancer. J Transl Med. 2020;18(1):331. doi:10.1186/s12967-020-02497-4.
   PubMed Web of Science ®Google Scholar
• Loyez M, Larrieu JC, Chevineau S, et al. In situ cancer diagnosis through online plasmonics. Biosens Bioelectron. 2019;131:104–112. doi:10.1016/j.bios.2019.01.062.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Deng Y, et al. Fraxetin suppresses proliferation of non-small-cell lung cancer cells via preventing activation of signal transducer and activator of transcription 3. Tohoku J Exp Med. 2019;248(1):3–12. doi:10.1620/tjem.248.3.
   PubMed Web of Science ®Google Scholar
• Tannenbaum SL, Koru-Sengul T, Zhao W, et al. Survival disparities in non-small cell lung cancer by race, ethnicity, and socioeconomic status. Cancer J. 2014;20(4):237–245. doi:10.1097/PPO.0000000000000058.
   PubMed Web of Science ®Google Scholar
• Birring SS, Peake MD. Symptoms and the early diagnosis of lung cancer. Thorax. 2005;60(4):268–269. doi:10.1136/thx.2004.032698.
   PubMed Web of Science ®Google Scholar
• Jain D, Nambirajan A, Chen G, et al. NSCLC subtyping in conventional cytology: Results of the international association for the study of lung cancer cytology working group survey to determine specific cytomorphologic criteria for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol. 2022;17(6):793–805. doi:10.1016/j.jtho.2022.02.013.
   PubMed Web of Science ®Google Scholar
• Lin J, Yu Y, Zhang X, et al. Classification of histological types and stages in non-small cell lung cancer using radiomic features based on CT images. J Digit Imaging. 2023;36(3):1029–1037. doi:10.1007/s10278-023-00792-2.
   PubMed Web of Science ®Google Scholar
• Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021;22(16):8661. doi:10.3390/ijms22168661.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84. doi:10.1016/j.lungcan.2014.07.020.
   PubMed Web of Science ®Google Scholar
• Xie W, Yuan S, Sun Z, et al. Long noncoding and circular RNAs in lung cancer: advances and perspectives. Epigenomics. 2016;8(9):1275–1287. doi:10.2217/epi-2016-0036.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Luo Y, Zhang C, et al. An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer. Cancer Cell Int. 2021;21(1):691. doi:10.1186/s12935-021-02357-1.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhang Z, Bao S, et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020;8(1):e000110. doi:10.1136/jitc-2019-000110.
   PubMed Web of Science ®Google Scholar
• Cao K, Liu M, Ma K, et al. Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma. Cancer Immunol Immunother. 2022;71(6):1295–1311. doi:10.1007/s00262-021-03069-1.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang J, Zheng N, et al. The role of neutrophil extracellular traps in cancer metastasis. Clin Transl Med. 2020;10(6):e126.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu Q, Zhang X, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature. 2020;583(7814):133–138. doi:10.1038/s41586-020-2394-6.
   PubMed Web of Science ®Google Scholar
• Fang C, Liu F, Wang Y, et al. A innovative prognostic symbol based on neutrophil extracellular traps (NETs)-related lncRNA signature in non-small-cell lung cancer. Aging. 2021;13(13):17864–17879. doi:10.18632/aging.203289.
   PubMedGoogle Scholar
• Li JP, Li R, Liu X, et al. A seven immune-related lncRNAs model to increase the predicted value of lung adenocarcinoma. Front Oncol. 2020;10:560779. doi:10.3389/fonc.2020.560779.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Yang H, Cheng P, et al. Bioinformatic analysis of the prognostic value of the lncRNAs encoding snoRNAs in hepatocellular carcinoma. Biofactors. 2019;45(2):244–252. doi:10.1002/biof.1478.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen J, Yang L, et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019;21(4):498–510. doi:10.1038/s41556-019-0299-0.
   PubMed Web of Science ®Google Scholar
• Balihodzic A, Barth DA, Prinz F, et al. Involvement of long non-coding RNAs in glucose metabolism in cancer. Cancers (Basel). 2021;13(5):977. doi:10.3390/cancers13050977.
   PubMed Web of Science ®Google Scholar
• Mai S, Liang L, Mai G, et al. Development and validation of lactate metabolism-related lncRNA signature as a prognostic model for lung adenocarcinoma. Front Endocrinol. 2022;13:829175. doi:10.3389/fendo.2022.829175.
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis. Gastroenterology. 2020;158(2):291–302. doi:10.1053/j.gastro.2019.08.059.
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502. doi:10.1016/S0140-6736(13)61649-9.
   PubMed Web of Science ®Google Scholar
• Burnett-Hartman AN, Lee JK, Demb J, et al. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset colorectal cancer. Gastroenterology. 2021;160(4):1041–1049. doi:10.1053/j.gastro.2020.12.068.
   PubMed Web of Science ®Google Scholar
• Kastenberg D, Bertiger G, Brogadir S. Bowel preparation quality scales for colonoscopy. World J Gastroenterol. 2018;24(26):2833–2843. doi:10.3748/wjg.v24.i26.2833.
   PubMed Web of Science ®Google Scholar
• Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull. 2002;64(1):27–43. doi:10.1093/bmb/64.1.27.
   PubMedGoogle Scholar
• Sun F, Liang W, Qian J. The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis. Mol Med Rep. 2019;20(4):3583–3596. doi:10.3892/mmr.2019.10588.
   PubMed Web of Science ®Google Scholar
• Liu S, Cao Q, Yan AG, et al. L: identification of the 3-lncRNA signature as a prognostic biomarker for colorectal cancer. Int J Mol Sci. 2020;21(24):9359. doi:10.3390/ijms21249359.
   Web of Science ®Google Scholar
• Cheng L, Han T, Zhang Z, et al. Identification and validation of six autophagy-related long non-coding RNAs as prognostic signature in colorectal cancer. Int J Med Sci. 2021;18(1):88–98. doi:10.7150/ijms.49449.
   PubMed Web of Science ®Google Scholar
• Zhou J, Lin J, Zhang H, et al. LncRNA HAND2-AS1 sponging miR-1275 suppresses colorectal cancer progression by upregulating KLF14. Biochem Biophys Res Commun. 2018;503(3):1848–1853. doi:10.1016/j.bbrc.2018.07.125.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Li L, Hou Z, et al. LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer. Cell Signal. 2020;66:109483. doi:10.1016/j.cellsig.2019.109483.
   PubMed Web of Science ®Google Scholar
• Gaur AB, Holbeck SL, Colburn NH, et al. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol. 2011;13(6):580–590. doi:10.1093/neuonc/nor033.
   PubMed Web of Science ®Google Scholar
• Wei NA, Liu SS, Leung TH, et al. Loss of programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer. 2009;8(1):70. doi:10.1186/1476-4598-8-70.
   PubMedGoogle Scholar
• Bian Z, Jin L, Zhang J, et al. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6(1):23892. doi:10.1038/srep23892.
   PubMed Web of Science ®Google Scholar
• Xue YB, Ding MQ, Xue L, et al. CircAGFG1 sponges miR-203 to promote EMT and metastasis of non-small-cell lung cancer by upregulating ZNF281 expression. Thorac Cancer. 2019;10(8):1692–1701. doi:10.1111/1759-7714.13131.
   PubMed Web of Science ®Google Scholar
• Qin CJ, Bu PL, Zhang Q, et al. ZNF281 regulates cell proliferation, migration and invasion in colorectal cancer through wnt/β-catenin signaling. Cell Physiol Biochem. 2019;52(6):1503–1516.
   PubMedGoogle Scholar
• Zhuang ST, Cai YJ, Liu HP, et al. LncRNA NEAT1/miR-185-5p/IGF2 axis regulates the invasion and migration of Colon cancer. Mol Genet Genomic Med. 2020;8(4):e1125.
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang G, Ren W, et al. LncRNA NEAT1 regulates 5-Fu sensitivity, apoptosis and invasion in colorectal cancer through the MiR-150-5p/CPSF4 axis. Onco Targets Ther. 2020;13:6373–6383. doi:10.2147/OTT.S239432.
   PubMed Web of Science ®Google Scholar
• Chen B, Dragomir MP, Fabris L, et al. The long noncoding RNA CCAT2 induces chromosomal instability through BOP1-AURKB signaling. Gastroenterology. 2020;159(6):2146–2162.e2133. doi:10.1053/j.gastro.2020.08.018.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hu H, Yuan Z, et al. LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness. Cell Death Dis. 2020;11(11):962. doi:10.1038/s41419-020-03164-8.
   PubMed Web of Science ®Google Scholar
• Xing Y, Zhao Z, Zhu Y, et al. Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma. Oncol Rep. 2018;39(5):2365–2375. doi:10.3892/or.2018.6324.
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu L, Weng S, et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13(1):816. doi:10.1038/s41467-022-28421-6.
   PubMed Web of Science ®Google Scholar
• Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165–176. doi:10.1016/j.tcb.2015.10.014.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–285. doi:10.1016/j.cell.2017.09.021.
   PubMed Web of Science ®Google Scholar
• Xu T, Ding W, Ji X, et al. Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med. 2019;23(8):4900–4912. doi:10.1111/jcmm.14511.
   PubMed Web of Science ®Google Scholar
• Wu Z, Lu Z, Li L, et al. Identification and validation of ferroptosis-related LncRNA signatures as a novel prognostic model for colon cancer. Front Immunol. 2021;12:783362. doi:10.3389/fimmu.2021.783362.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411): earr3593. doi:10.1126/science.aar3593.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39(1):204. doi:10.1186/s13046-020-01709-5.
   PubMed Web of Science ®Google Scholar
• Luan L, Dai Y, Shen T, et al. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Front Immunol. 2022;13:951455. doi:10.3389/fimmu.2022.951455.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Wen Y, Xuan C, et al. Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis. FEBS Open Bio. 2020;10(4):674–688. doi:10.1002/2211-5463.12805.
   PubMed Web of Science ®Google Scholar
• Zhao F, Wang J, Chen M, et al. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients. Clin Transl Med. 2019;8(1):30.
   PubMed Web of Science ®Google Scholar
• Cui PF, Cong XF, Gao F, et al. Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: a study of 1358 patients. World J Clin Cases. 2020;8(1):54–67. doi:10.12998/wjcc.v8.i1.54.
   PubMed Web of Science ®Google Scholar
• Nevedomskaya E, Baumgart SJ. Haendler B: recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci. 2018;19(5):1359. doi:10.3390/ijms19051359.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–262. doi:10.1016/j.eururo.2015.11.005.
   PubMed Web of Science ®Google Scholar
• Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly diagnosed metastatic prostate cancer: has the paradigm changed? Urol Clin North Am. 2017;44(4):611–621. doi:10.1016/j.ucl.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Li C, Hu J, Hu X, et al. LncRNA SNHG9 is a prognostic biomarker and correlated with immune infiltrates in prostate cancer. Transl Androl Urol. 2021;10(1):215–226. doi:10.21037/tau-20-1134.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen Z, Mo J, et al. Identification of HCG18 and MCM3AP-AS1 that associate with bone metastasis, poor prognosis and increased abundance of M2 macrophage infiltration in prostate cancer. Technol Cancer Res Treat. 2021;20:1533033821990064. doi:10.1177/1533033821990064.
   Web of Science ®Google Scholar
• Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146–162. doi:10.1038/s41422-019-0263-3.
   PubMed Web of Science ®Google Scholar
• Liu C, Gao Y, Ni J, et al. The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer. BMC Cancer. 2022;22(1):788. doi:10.1186/s12885-022-09876-8.
   PubMed Web of Science ®Google Scholar
• Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250–260. doi:10.1111/apt.12814.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209.
   PubMed Web of Science ®Google Scholar
• Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–279. doi:10.3322/caac.21657.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-5.
   PubMed Web of Science ®Google Scholar
• Tan Z. Recent advances in the surgical treatment of advanced gastric cancer: a review. Med Sci Monit. 2019;25:3537–3541. doi:10.12659/MSM.916475.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Taheri M. Long non-coding RNA signature in gastric cancer. Exp Mol Pathol. 2020;113:104365. doi:10.1016/j.yexmp.2019.104365.
   PubMed Web of Science ®Google Scholar
• Lansdorp-Vogelaar I, Kuipers EJ. Screening for gastric cancer in Western countries. Gut. 2016;65(4):543–544. doi:10.1136/gutjnl-2015-310356.
   PubMed Web of Science ®Google Scholar
• Nie K, Deng Z, Zheng Z, et al. Identification of a 14-lncRNA signature and construction of a prognostic nomogram predicting overall survival of gastric cancer. DNA Cell Biol. 2020;39(9):1532–1544. doi:10.1089/dna.2020.5565.
   PubMed Web of Science ®Google Scholar
• Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. doi:10.1186/s13045-019-0720-y.
   PubMed Web of Science ®Google Scholar
• Wei J, Zeng Y, Gao X, et al. A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer. BMC Cancer. 2021;21(1):1221. doi:10.1186/s12885-021-08975-2.
   PubMed Web of Science ®Google Scholar
• Duan F, Song C, Wang P, et al. Polygenic risk scores for prediction of gastric cancer based on bioinformatics screening and validation of functional lncRNA SNPs. Clin Transl Gastroenterol. 2021;12(11):e00430. doi:10.14309/ctg.0000000000000430.
   PubMed Web of Science ®Google Scholar
• Zhu X, Tian X, Yu C, et al. A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer. 2016;15(1):60. doi:10.1186/s12943-016-0544-0.
   PubMed Web of Science ®Google Scholar
• Engreitz JM, Haines JE, Perez EM, et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature. 2016;539(7629):452–455. doi:10.1038/nature20149.
   PubMed Web of Science ®Google Scholar
• Tan YT, Lin JF, Li T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Communications. 2021;41(2):109–120. doi:10.1002/cac2.12108.
   PubMed Web of Science ®Google Scholar
• Pefanis E, Wang J, Rothschild G, et al. RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell. 2015;161(4):774–789. doi:10.1016/j.cell.2015.04.034.
   PubMed Web of Science ®Google Scholar
• Lin W, Huang Z, Xu Y, et al. A three-lncRNA signature predicts clinical outcomes in low-grade glioma patients after radiotherapy. Aging. 2020;12(10):9188–9204. doi:10.18632/aging.103189.
   PubMedGoogle Scholar
• Yu W, Ma Y, Hou W, et al. Identification of immune-related lncRNA prognostic signature and molecular subtypes for glioblastoma. Front Immunol. 2021;12:706936. doi:10.3389/fimmu.2021.706936.
   PubMed Web of Science ®Google Scholar
• Gao L, Lin P, Chen P, et al. A novel risk signature that combines 10 long noncoding RNAs to predict neuroblastoma prognosis. J Cell Physiol. 2020;235(4):3823–3834. doi:10.1002/jcp.29277.
   PubMed Web of Science ®Google Scholar
• Xu Z, Chen H, Sun J, et al. Multi-omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence. Bioengineered. 2021;12(2):11108–11125. doi:10.1080/21655979.2021.2000122.
   PubMed Web of Science ®Google Scholar
• Liu J, Cui J, Zhao S, et al. Ferroptosis-related long noncoding RNAs have excellent predictive ability for multiomic characteristics of bladder cancer. Oxid Med Cell Longev. 2022;2022:1–30. doi:10.1155/2022/9316847.
   Web of Science ®Google Scholar
• Chi H, Peng G, Wang R, et al. Cuprotosis programmed-cell-death-related lncRNA signature predicts prognosis and immune landscape in PAAD patients. Cells. 2022;11(21):3436. doi:10.3390/cells11213436.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Ren J, Li L, et al. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma. Bioengineered. 2021;12(1):2432–2448. doi:10.1080/21655979.2021.1933868.
   PubMed Web of Science ®Google Scholar
• Chen E, Yi J, Jiang J, et al. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer. BMC Cancer. 2022;22(1):1037. doi:10.1186/s12885-022-10122-4.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Z, Liu M, et al. Establishment of a lncRNA-based prognostic gene signature associated with altered immune responses in HCC. Front Immunol. 2022;13:880288. doi:10.3389/fimmu.2022.880288.
   PubMedGoogle Scholar
• Tian S, Tang M, Li J, et al. Identification of long non-coding RNA signatures for squamous cell carcinomas and adenocarcinomas. Aging. 2021;13(2):2459–2479. doi:10.18632/aging.202278.
   Google Scholar
• Qian L, Ni T, Fei B, et al. An immune-related lncRNA pairs signature to identify the prognosis and predict the immune landscape of laryngeal squamous cell carcinoma. BMC Cancer. 2022;22(1):545. doi:10.1186/s12885-022-09524-1.
   PubMed Web of Science ®Google Scholar
• Wang X, Lu Y, Liu Z, et al. A 9-LncRNA signature for predicting prognosis and immune response in diffuse large B-Cell lymphoma. Front Immunol. 2022;13:813031. doi:10.3389/fimmu.2022.813031.
   PubMedGoogle Scholar
• Liu W, Yang HS, Zheng SY, et al. Thymic epithelial tumors: examining the GTF2I mutation and developing a novel prognostic signature with LncRNA pairs to predict tumor recurrence. BMC Genomics. 2022;23(1):656. doi:10.1186/s12864-022-08880-3.
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhao H, Wang Z, et al. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 2015;34(1):102. doi:10.1186/s13046-015-0219-5.
   PubMedGoogle Scholar
• Zhong Q, Lu M, Yuan W, et al. Eight-lncRNA signature of cervical cancer were identified by integrating DNA methylation, copy number variation and transcriptome data. J Transl Med. 2021;19(1):58. doi:10.1186/s12967-021-02705-9.
   PubMed Web of Science ®Google Scholar
• Song Y, Qu H. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer. BMC Cancer. 2022;22(1):633. doi:10.1186/s12885-022-09591-4.
   PubMed Web of Science ®Google Scholar
• Niu L, Wu Z. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma. Aging (Albany NY). 2023;15(10):4236–4252. doi:10.18632/aging.204726.
   PubMedGoogle Scholar
• Zhu J, Deng J, Zhang L, et al. Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma. BMC Cancer. 2020;20(1):927. doi:10.1186/s12885-020-07302-5.
   PubMed Web of Science ®Google Scholar
• Rong J, Wang H, Yao Y, et al. Identification of m7G-associated lncRNA prognostic signature for predicting the immune status in cutaneous melanoma. Aging. 2022;14(12):5233–5249. doi:10.18632/aging.204151.
   PubMedGoogle Scholar
• Zhang YP, Cheng YB, Li S, et al. An epithelial-mesenchymal transition-related long non-coding RNA signature to predict overall survival and immune microenvironment in kidney renal clear cell carcinoma. Bioengineered. 2021;12(1):555–564. doi:10.1080/21655979.2021.1880718.
   PubMed Web of Science ®Google Scholar
• Li S, Ran MY, Qiao H. A cell cycle-related lncRNA signature predicts the progression-free interval in papillary thyroid carcinoma. Front Endocrinol. 2023;14:1110987. doi:10.3389/fendo.2023.1110987.
   PubMed Web of Science ®Google Scholar
• Liu B, Liu Z, Feng C, et al. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma. Front Endocrinol. 2022;13:987942. doi:10.3389/fendo.2022.987942.
   PubMed Web of Science ®Google Scholar
• Li J, Chen Z, Tian L, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. 2014;63(11):1700–1710. doi:10.1136/gutjnl-2013-305806.
   PubMed Web of Science ®Google Scholar